Breast Cancer Patients With 10 or More Involved Axillary Lymph Nodes Treated by Multimodality Therapy: Influence of Clinical Presentation on Outcome

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 2, 2007, Pages 364-369

  Geara, Fady B ^a   Nasr, Elie ^a   Tucker, Susan L ^b   Charafeddine, Maya ^a   Dabaja, Bouthaina ^a   Eid, Toufic ^a   Abbas, Jaber ^a   Salem, Ziad ^a   Shamseddine, Ali ^a   Issa, Philip ^a   El Saghir, Nagi ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Advanced disease; Breast cancer; Clinical presentation

Indexed keywords

CHEMOTHERAPY; DISEASES; LIVING SYSTEMS STUDIES; MULTIVARIABLE CONTROL SYSTEMS; TUMORS;

ADVANCED DISEASES; BREAST CANCER; CLINICAL PRESENTATION; MULTIVARIATE ANALYSIS;

PATIENT TREATMENT;

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS;

EID: 34247846125     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.12.027     Document Type: Article

References (22)

1. Nemoto T., Vara J., Bedwani R.N., Baker, et al. Management and survival of female breast cancer: Results of a national survey of the American College of Surgeons. Cancer 45 (1980) 2917-2924
2. Carter C.L., Allen C., and Henson D.E. Relationship of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
3. Fisher E.R., Gregorio R.M., Fisher B., et al. The pathology of invasive breast cancer. Cancer 36 (1975) 1-85
4. Donegan W.L., and Lewis D. Clinical diagnosis and staging of breast cancer. Semin Oncol 5 (1978) 373-384
5. Fowble B., Gray R., Gilchrist K., et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6 (1988) 1107-1111
6. Buchholz T.A., Woodward W.A., Tucker S.L., et al. Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. [abstract]. J Clin Oncol 22 (2004) 555
7. Rodenhuis S., Richel D.J., van der Wall E., et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352 (1998) 515-521
8. Zander A.R., Kroger N., Schmoor C., et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol 22 (2004) 2273-2283
9. Hortobagyi G.N., Buzdar A.U., Theriault R.L., et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92 (2000) 225-233
10. Tallman M.S., Gray R., Robert N.J., et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349 (2003) 17-26
11. Schrama J.G., Faneyte I.F., Schornagel J.H., et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Ann Oncol 13 (2002) 689-698
12. Coombes R.C., Howell A., Emson M., et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: Long-term results of an international randomised trial. Ann Oncol 16 (2005) 726-734
13. Farquhar C., Marjoribanks J., Basser R., et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev (2005) (3):CD003139
14. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355 (2000) 1757-1770
15. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 (1997) 956-962
16. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 (1997) 949-955
17. Strom E.A., McNeese M.D., Fletcher G.H., et al. Results of mastectomy and postoperative irradiation in the management of locoregionally advanced carcinoma of the breast. Int J Radiat Oncol Biol Phys 21 (1991) 319-323
18. Diab S.G., Hilsenbeck S.G., de Moor C., et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16 (1998) 1655-1660
19. Jabro G., Wazer D.E., Ruthazer R., et al. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes. Int J Radiat Oncol Biol Phys 44 (1999) 273-280
20. Nitz U.A., Mohrmann S., Fischer J., et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366 (2005) 1935-1944
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365 (2005) 1687-1717
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366 (2005) 2087-2106